Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCA | P17252 | 4/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | DGKA | P23743 | 1/20 | 0.39 |
| ▸ | FAAH | O00519 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21471824 | 1.00 | PRKCA (0.45) | PRKCAKDM4EDUSP3MEN1KMT2A | |
| SCHEMBL19300939 | 0.91 | PRKCA (0.41) | PRKCAKDM4EDUSP3MEN1KMT2A | |
| SCHEMBL20370764 | 0.91 | PRKCA (0.41) | PRKCAKDM4EDUSP3MEN1KMT2A | |
| SCHEMBL2552726 | 0.89 | KDM4E (0.53) | PRKCAKDM4EDUSP3MEN1KMT2A | |
| SCHEMBL15319570 | 0.89 | KDM4E (0.53) | PRKCAKDM4EDUSP3MEN1KMT2A | |
| SCHEMBL8947454 | 0.84 | LMNA (0.54) | PRKCAKDM4EDUSP3MEN1KMT2A | |
| SCHEMBL25180175 | 0.83 | PRKCA (0.51) | PRKCALMNAMAPT | |
| 3-Hydroxybutyric Acid, (+/-)- SCHEMBL22300929 | 0.83 | KDM4E (0.47) | PRKCAKDM4EDUSP3MEN1KMT2A | |
| 3-Hydroxybutyric Acid, (+/-)- SCHEMBL19976113 | 0.83 | KDM4E (0.47) | PRKCAKDM4EDUSP3MEN1KMT2A | |
| SCHEMBL25476040 | 0.83 | KDM4E (0.47) | PRKCAKDM4EDUSP3MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200352894-A1 | COMBINATION THERAPY | RA CAPITAL HEALTHCARE FUND, L.P. | 2020-11-12 | — | — | US | disclosed |
| US-10786476-B2 | Combination therapy | IMBRIA PHARMACEUTICALS, INC. (US) | 2020-09-29 | — | — | US | disclosed |
| US-20190314319-A1 | COMBINATION THERAPY | IMBRIA PHARMACEUTICALS, INC. | 2019-10-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200352894-A1 | COMBINATION THERAPY | PC, ABAT, CKMT1A; CKMT1B | PRKCA 867/4885KDM4E 1383/4885DUSP3 3668/4885 |
| US-20190314319-A1 | COMBINATION THERAPY | PC, ABAT, CKMT1A; CKMT1B | PRKCA 867/4885KDM4E 1383/4885DUSP3 3668/4885 |
| US-10786476-B2 | Combination therapy | PC, ABAT, CKMT1A; CKMT1B | PRKCA 867/4885KDM4E 1383/4885DUSP3 3668/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.